Get all premium features to the best stock analysis tool

FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair

March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures , supporting treatment [2] DeviceGuide integrates with Philips Azurion image-guided therapy platform that combines imaging, real-time data and intelligent software within a unified workflow to support more consistent, efficient and confidently guided minimally invasive procedures Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered software solution that assists physicians during one of interventional cardiology's most technically demanding procedures – repairing leaking mitral valves through a minimally invasive approach. DeviceGuide was developed in close collaboration with Edwards Lifesciences, the global leader in structural heart innovation, aligning Philips' imaging and AI expertise with Edwards' expertise in valvular heart therapy development.

Philips launches IntraSight Plus to simplify coronary interventions and advance precision care

March 25, 2026 Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient care With FDA clearance and CE marking, IntraSight Plus streamlines the workflow efficiency of minimally invasive coronary procedures and can enable system operation time savings up to 47% in both the USA and Europe Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the launch of its intuitive interventional guidance platform, IntraSight Plus, which is cleared for clinical use in the USA and Europe. With CE marking and FDA 510(k) clearance, the redesigned platform combines the most comprehensive diagnostic and treatment planning tools to deliver efficiency, simplicity and precision in a single intuitive system [1].

Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant

March 24, 2026 Philips ranks No. 1 among medical technology companies in the European Patent Office Technology Dashboard 2025, filing 1,289 patent applications with the EPO in 2025.

Philips convenes the Annual General Meeting of Shareholders 2026

March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: Proposal to appoint John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.